ClinicalTrials.gg
Active, not recruitingNCT07168356B-KindUpdated May 22, 2026

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

A Phase 1 interventional study of Bepirovirsen in Hepatitis B, sponsored by GlaxoSmithKline. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
12th of 16
32 · median 103
Started
2025
the only one that year
Phase 1
5 of 16
1 open now
Registered
13th of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 12th largest by enrollment, is the only one that started in 2025, is one of 5 in phase 1, and was the 13th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.

03

Conditions studied

  • Hepatitis B

Keywords

  • Bepirovirsen
  • Pharmacokinetics
  • Severe renal impairment
  • Moderate renal impairment
  • Healthy participants
  • Renal function
  • Kidney disease
  • Hepatitis B
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years, inclusive
  • Body weight greater than or equal to 50 kilograms (kg) and (BMI) within the range 19 to 40 kilograms per square meter (kg/m\^2).
  • Males and females may participate. Female participants must not be pregnant or breastfeeding, and must be of non-, or agree to use a highly effective method of .
  • Capable of giving signed Additional inclusion criteria for renal impairment groups (Group 1 and Group 2)
  • Severe renal impairment [estimated (eGFR) adjusted for actual body surface area (BSA) less than 30 milliliters per minute (ml/min); Group 1] or moderate renal impairment [eGFR adjusted for actual BSA between 30 and 59 ml/min; Group 2], from any cause other than vasculitis or glomerulonephritis Additional inclusion criteria for healthy control participants with normal renal function (Group 3)
  • Healthy, based on medical evaluation including medical history, physical examination, laboratory tests, and (ECG).
  • Normal renal function (eGFR adjusted for actual BSA greater than or equal to 90 ml/min)

Exclusion criteria

Exclusion Criteria:

  • Any medical condition that could affect the absorption, metabolism, or elimination of drugs, increase the risk of taking part in the study, or interfere with interpretation of the study data.
  • History of vasculitis or any type of glomerulonephritis
  • Use of creatine-containing supplements within 30 days of screening or intended use during the study.
  • Current enrolment in another interventional study, or past participation in a study where an medicine, vaccine or device was administered if, at the time of consent, it is within 5 half-lives or twice the duration of the biological effect (whichever is longer) of the product given in the previous study.
  • Received any oligonucleotide or small interfering ribonucleic acid (siRNA) within the past 12 months.
  • Exposure to more than 4 investigational products within the past 12 months.
  • A positive blood test for , , or (HIV).
  • Average weekly alcohol intake of greater than 14 drinks for males or greater than 7 drinks for females.
  • Current substance misuse or dependence, or a previous history of substance misuse or dependence that could interfere with ability to participate in the study.

Additional exclusion criteria for renal impairment groups (Group 1 and Group 2)

  • History of renal transplantation or anticipated renal transplant during the study.
  • On dialysis or likely to require dialysis during the study.
  • Positive drug or alcohol screen (unless because of prescribed medication). Additional exclusion criterion for healthy control group (Group 3)
  • Positive drug or alcohol screen.
  • Urine albumin-to-creatinine ratio (uACR) > 0.3 mg/mg (300 mg/g).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group 1- Severe Renal Impairment Participants

    Participants with severe renal impairment will receive Bepirovirsen.

    Drug: Bepirovirsen

  • Experimental
    Group 2- Moderate Renal Impairment Participants

    Participants with moderate renal impairment will receive Bepirovirsen.

    Drug: Bepirovirsen

  • Experimental
    Group 3-Healthy Control Participants

    Healthy control participants will receive Bepirovirsen.

    Drug: Bepirovirsen

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma Area Under the Concentration Time Curve From Time Zero (Pre-Dose) Extrapolated to Infinite Time [AUC(0-∞)] of Bepirovirsen

    Time frame: Up to Day 50

  2. Maximum Observed Concentration (Cmax) of Bepirovirsen

    Time frame: Up to Day 50

Secondary outcomes

  1. Plasma Area Under the Concentration Time Curve From Time Zero (Pre-Dose) to 24 hours [AUC(0-24)] of Bepirovirsen

    Time frame: Up to 24 hours

  2. Plasma Area Under the Concentration Time Curve From Time Zero (Pre-Dose) to 168 hours (Day 8) [AUC(0-168)] of Bepirovirsen

    Time frame: Up to 168 hours

  3. Observed Concentration of Bepirovirsen on Day 8

    Time frame: At Day 8

  4. Apparent Terminal Phase Half-life (t1/2) of Bepirovirsen

    Time frame: Up to Day 50

  5. Apparent Clearance (CL/F) of Bepirovirsen

    Time frame: Up to Day 50

  6. Time of Occurrence of Cmax (Tmax) of Bepirovirsen

    Time frame: Up to Day 50

  7. Apparent Terminal Phase Volume of Distribution (Vz/F) of Bepirovirsen

    Time frame: Up to Day 50

07

Study locations

3 sites
  • GSK Investigational Site
    Orlando, Florida 32809, United States
  • GSK Investigational Site
    Tampa, Florida 33603, United States
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Mar 2026, 5 months.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 5 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 11, 2025
StartActual
Sep 26, 2025
Primary completionActual
Mar 3, 2026
CompletionEst.
Aug 18, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07168356
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Sep 26, 2025
Primary completion
Mar 3, 2026
Completion
Aug 18, 2026 (estimated)
Last update
May 22, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion